STRATA Skin Sciences Inc  

(Public, NASDAQ:SSKN)   Watch this stock  
Find more results for NASDAQ:MELA
0.670
-0.020 (-2.90%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.66 - 0.73
52 week 0.51 - 1.53
Open 0.68
Vol / Avg. 78,198.00/26,880.00
Mkt cap 7.06M
P/E     -
Div/yield     -
EPS -2.46
Shares 10.59M
Beta 0.10
Inst. own 22%
Sep 29, 2016
MELA Sciences Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Aug 11, 2016
Q2 2016 STRATA Skin Sciences Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 11, 2016
Q2 2016 STRATA Skin Sciences Inc Earnings Release - 4:00PM EDT - Add to calendar
May 12, 2016
Q1 2016 STRATA Skin Sciences Inc Earnings Call - Webcast
May 12, 2016
Q1 2016 STRATA Skin Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -18.86% -134.89%
Operating margin -28.06% -89.08%
EBITD margin - -67.17%
Return on average assets -11.81% -71.13%
Return on average equity -37.05% -196.81%
Employees 106 -
CDP Score - -

Address

100 Lakeside Dr Ste 100
HORSHAM, PA 19044-2352
United States - Map
+1-215-6193200 (Phone)
+1-215-6193208 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company's technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.

Officers and directors

Jeffrey F. O'Donnell Sr. Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Michael R. Stewart President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Christina L. Allgeier CPA Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
R. Rox Anderson M.D. Director
Bio & Compensation  - Reuters
David K. Stone Director
Age: 58
Bio & Compensation  - Reuters
Kathryn B. Swintek Director
Age: 62
Bio & Compensation  - Reuters
LuAnn Via Director
Age: 61
Bio & Compensation  - Reuters
Samuel E. Navarro Independent Director
Age: 59
Bio & Compensation  - Reuters